Insider Selling: Alto Neuroscience (NYSE:ANRO) COO Sells 70,000 Shares of Stock

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) COO Jr. Michael Conick Hanley sold 70,000 shares of the stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $27.68, for a total transaction of $1,937,600.00. Following the sale, the chief operating officer owned 17,729 shares in the company, valued at $490,738.72. The trade was a 79.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jr. Michael Conick Hanley also recently made the following trade(s):

  • On Wednesday, November 18th, Jr. Michael Conick Hanley sold 2,896 shares of Alto Neuroscience stock. The shares were sold at an average price of $26.48, for a total transaction of $76,686.08.
  • On Tuesday, November 17th, Jr. Michael Conick Hanley sold 2,104 shares of Alto Neuroscience stock. The shares were sold at an average price of $26.82, for a total transaction of $56,429.28.

Alto Neuroscience Stock Up 3.4%

Shares of Alto Neuroscience stock traded up $0.85 on Wednesday, reaching $25.77. 986,145 shares of the stock were exchanged, compared to its average volume of 597,641. The firm’s 50 day moving average is $25.83 and its 200-day moving average is $24.79. Alto Neuroscience, Inc. has a one year low of $12.51 and a one year high of $37.48. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.12 and a current ratio of 18.12.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.13. On average, sell-side analysts forecast that Alto Neuroscience, Inc. will post -2.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ANRO has been the topic of several recent analyst reports. Wedbush lifted their price target on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. BTIG Research reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Alto Neuroscience in a research note on Wednesday, November 11th. Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Finally, Zacks Research upgraded Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.88.

Check Out Our Latest Analysis on Alto Neuroscience

Hedge Funds Weigh In On Alto Neuroscience

Several large investors have recently bought and sold shares of ANRO. Goldman Sachs Group Inc. increased its position in Alto Neuroscience by 70.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 404,674 shares of the company’s stock valued at $10,331,000 after acquiring an additional 167,844 shares during the period. Bellevue Group AG bought a new position in shares of Alto Neuroscience during the third quarter valued at $29,706,000. Marshall Wace LLP lifted its holdings in shares of Alto Neuroscience by 281.1% during the third quarter. Marshall Wace LLP now owns 859,309 shares of the company’s stock worth $21,938,000 after purchasing an additional 633,806 shares during the period. Empowered Funds LLC bought a new stake in shares of Alto Neuroscience in the third quarter worth $299,000. Finally, HighVista Strategies LLC bought a new stake in shares of Alto Neuroscience in the third quarter worth $922,000.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

Featured Articles

Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.